Clinical trials
Connective Tissue Diseases trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 8 |
| Unknown status | 6 |
| Active, not recruiting | 4 |
| Completed | 3 |
| Enrolling by invitation | 2 |
| Terminated | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Qilu Hospital of Shandong University | 3 |
| Bristol-Myers Squibb | 2 |
| GlaxoSmithKline | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| RenJi Hospital | 2 |
| United Therapeutics | 2 |
| Beeline Medicines Corporation | 1 |
| Beijing Hospital | 1 |
| Biogen | 1 |
| Changhai Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Connective Tissue Diseases | 26 |
| Autoimmune Diseases | 8 |
| Lung Diseases, Interstitial | 6 |
| Lupus Erythematosus, Systemic | 6 |
| Immune System Diseases | 5 |
| Arthritis, Rheumatoid | 4 |
| Lung Diseases | 3 |
| Scleroderma, Systemic | 3 |
| Arthritis | 2 |
| Cardiovascular Diseases | 2 |
Trials
Showing 76 to 26 of 26. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.